Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.99 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Protara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 66 | 84 | 91 | 169 | 6 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 2 | 1 | 1 |
Total Current Assets | 69 | 86 | 93 | 169 | 7 |
Net Property & Equipment | 1 | 2 | 2 | 1 | 0 |
Investments & Advances | 0 | 18 | 39 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 30 | 30 | 0 |
Deposits & Other Assets | 4 | 1 | 2 | 3 | 0 |
Total Assets | 79 | 113 | 173 | 203 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 2 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 6 | 6 | 4 | 3 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 11 | 11 | 4 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 18 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 269 | 263 | 256 | 246 | 213 |
Retained Earnings | -200 | -160 | -94 | -47 | -225 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 68 | 102 | 162 | 199 | 6 |
Total Liabilities & Shareholder's Equity | 79 | 113 | 173 | 203 | 7 |
Total Common Equity | 68 | 102 | 162 | 199 | -12 |
Shares Outstanding | 11.30 | 11.20 | 11.20 | 11.20 | 0.50 |
Book Value Per Share | 6.05 | 9.11 | 14.46 | 17.79 | -24.14 |
Fiscal Year End for Protara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 90 | 55 | 66 | 74 | 80 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 3 | 4 | 4 |
Total Current Assets | 92 | 58 | 69 | 78 | 84 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 4 | 4 | 4 | 4 |
Total Assets | 102 | 68 | 79 | 88 | 95 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 4 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 6 | 6 | 6 | 7 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 10 | 11 | 12 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 313 | 270 | 269 | 267 | 266 |
Retained Earnings | -221 | -211 | -200 | -190 | -180 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 92 | 58 | 68 | 77 | 85 |
Total Liabilities & Shareholder's Equity | 102 | 68 | 79 | 88 | 95 |
Total Common Equity | 92 | 58 | 68 | 77 | 85 |
Shares Outstanding | 20.50 | 11.40 | 11.30 | 11.30 | 11.30 |
Book Value Per Share | 4.49 | 5.12 | 6.05 | 6.81 | 7.54 |